Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 15/20 | 0.84 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.57 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.52 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5129623 | 0.94 | PTGER1 (0.75) | PTGER1TBXA2RSHMT1SHMT2KDM4E | |
| SCHEMBL4721023 | 0.90 | PTGER1 (0.70) | PTGER1TBXA2RSHMT1SHMT2CYP2C9 | |
| SCHEMBL14098698 | 0.89 | PTGER1 (0.78) | PTGER1TBXA2RSHMT1SHMT2KMT2A | |
| SCHEMBL5121721 | 0.88 | PTGER1 (0.67) | PTGER1TBXA2RSHMT1SHMT2KDM4E | |
| SCHEMBL4723494 | 0.87 | PTGER1 (0.74) | PTGER1TBXA2RKMT2ACYP2C9 | |
| SCHEMBL5125104 | 0.87 | PTGER1 (0.66) | PTGER1TBXA2RSHMT1SHMT2KDM4E | |
| SCHEMBL5117064 | 0.87 | PTGER1 (0.64) | PTGER1CYP2C9KDM4EALDH1A1GAA | |
| SCHEMBL5119199 | 0.86 | PTGER1 (0.64) | PTGER1SHMT1SHMT2CYP2C9KDM4E | |
| SCHEMBL5115968 | 0.84 | PTGER1 (0.61) | PTGER1TBXA2RSHMT1SHMT2CYP2C9 | |
| SCHEMBL5129850 | 0.83 | PTGER1 (0.60) | PTGER1TBXA2RSHMT1SHMT2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| EP-1874776-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006114274-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | PTGER1, PTGER2, PTGER4 | PTGER1 1/4885TBXA2R 10/4885SHMT1 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.